
1. indian j gastroenterol. 2016 nov;35(6):405-418. epub 2016 oct 31.

hepatic porphyria: narrative review.

arora s(1), young s(1), kodali s(1)(2), singal ak(3)(4).

author information: 
(1)department internal medicine, uab university alabama birmingham,
birmingham, al, usa.
(2)division gastroenterology hepatology, uab university alabama in
birmingham, birmingham, al, usa.
(3)department internal medicine, uab university alabama birmingham,
birmingham, al, usa. ashwanisingal.com@gmail.com.
(4)division gastroenterology hepatology, uab university alabama in
birmingham, birmingham, al, usa. ashwanisingal.com@gmail.com.

porphyrias group metabolic disorders, result specific
abnormality one eight enzymes heme biosynthetic pathway. these
have subdivided based predominant site enzyme defect hepatic 
and erythropoietic types based clinical presentation acute
neurovisceral cutaneous blistering porphyrias. review focuses hepatic
porphyrias, include acute intermittent porphyria (aip), variegate porphyria
(vp), hereditary coproporphyria (hcp), aminolevulinic acid dehydratase deficiency
porphyria (adp), porphyria cutanea tarda (pct). these, aip adp are
classified acute porphyria, pct cutaneous, vp hcp present with
both acute cutaneous clinical manifestations. porphobilinogen levels a
spot urine sample initial screening test diagnosis acute
hepatic porphyria, plasma spot urine porphyrin levels initial
screening test approach patients suspected cutaneous porphyria. specific
biochemical porphyrin profile porphyria helps determining the
specific diagnosis. pain relief elimination triggering agents the
initial steps managing patient presenting acute attack. intravenous 
glucose administration terminates mild episode acute porphyria, with
intravenous hemin needed management moderate severe episodes. liver
transplantation curative may needed patients a
life-threatening acute porphyria attack patients recurrent acute
attacks refractory prophylactic treatment. cutaneous porphyrias, pct is
the common frequently associated combination multiple
susceptibility factors alcohol use, smoking, hepatitis c virus infection,
hiv infection, estrogen use, mutations hemochromatosis gene. regular
phlebotomy schedule low-dose hydroxychloroquine effective safe
treatment options management pct.

doi: 10.1007/s12664-016-0698-0 
pmid: 27796941  [indexed medline]

